Bank of America restated their buy rating on shares of UnitedHealth Group (NYSE:UNH) in a research report released on Wednesday, Briefing.com Automated Import reports. The firm currently has a $290.00 price target on the healthcare conglomerate’s stock, down from their prior price target of $320.00.

Other research analysts have also issued reports about the stock. Morgan Stanley cut their target price on shares of UnitedHealth Group from $315.00 to $285.00 and set an overweight rating on the stock in a research note on Wednesday. SunTrust Banks cut their target price on shares of UnitedHealth Group to $300.00 and set a buy rating on the stock in a research note on Wednesday. They noted that the move was a valuation call. Credit Suisse Group reissued a buy rating and set a $310.00 target price on shares of UnitedHealth Group in a research note on Friday, February 8th. Zacks Investment Research lowered shares of UnitedHealth Group from a buy rating to a hold rating in a research note on Tuesday, December 18th. Finally, Cleveland Research reissued a buy rating on shares of UnitedHealth Group in a research note on Friday, January 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $291.56.

Shares of NYSE UNH opened at $221.75 on Wednesday. The firm has a market cap of $212.78 billion, a P/E ratio of 17.22, a P/E/G ratio of 1.18 and a beta of 0.79. UnitedHealth Group has a 12-month low of $208.07 and a 12-month high of $287.94. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.73 and a current ratio of 0.73.

UnitedHealth Group (NYSE:UNH) last issued its earnings results on Tuesday, April 16th. The healthcare conglomerate reported $3.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.60 by $0.13. The business had revenue of $60.30 billion for the quarter, compared to analyst estimates of $59.72 billion. UnitedHealth Group had a net margin of 5.30% and a return on equity of 24.38%. UnitedHealth Group’s revenue was up 9.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.04 earnings per share. Equities research analysts predict that UnitedHealth Group will post 14.63 earnings per share for the current fiscal year.

In other UnitedHealth Group news, Director Gail R. Wilensky sold 2,930 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $253.39, for a total value of $742,432.70. Following the transaction, the director now directly owns 64,726 shares of the company’s stock, valued at $16,400,921.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard T. Burke sold 5,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $245.01, for a total transaction of $1,225,050.00. Following the completion of the transaction, the director now directly owns 182,372 shares in the company, valued at $44,682,963.72. The disclosure for this sale can be found here. Insiders sold 17,930 shares of company stock worth $4,587,133 over the last ninety days. Insiders own 0.87% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the business. CI Investments Inc. raised its holdings in shares of UnitedHealth Group by 5.8% in the third quarter. CI Investments Inc. now owns 949,719 shares of the healthcare conglomerate’s stock valued at $252,663,000 after purchasing an additional 52,023 shares during the last quarter. Martingale Asset Management L P raised its holdings in shares of UnitedHealth Group by 1.7% in the third quarter. Martingale Asset Management L P now owns 214,133 shares of the healthcare conglomerate’s stock valued at $56,969,000 after purchasing an additional 3,598 shares during the last quarter. Blue Fin Capital Inc. raised its holdings in shares of UnitedHealth Group by 7.2% in the third quarter. Blue Fin Capital Inc. now owns 10,689 shares of the healthcare conglomerate’s stock valued at $2,844,000 after purchasing an additional 722 shares during the last quarter. Capital Guardian Trust Co. raised its holdings in shares of UnitedHealth Group by 0.6% in the third quarter. Capital Guardian Trust Co. now owns 276,790 shares of the healthcare conglomerate’s stock valued at $73,637,000 after purchasing an additional 1,571 shares during the last quarter. Finally, Bamco Inc. NY raised its holdings in shares of UnitedHealth Group by 230.0% in the third quarter. Bamco Inc. NY now owns 2,419 shares of the healthcare conglomerate’s stock valued at $644,000 after purchasing an additional 1,686 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Featured Article: Conference Calls and Individual Investors

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.